Fluidigm Corp
F:FLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Fluidigm Corp
Accrued Liabilities
Fluidigm Corp
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluidigm Corp
F:FLB
|
Accrued Liabilities
$35.3m
|
CAGR 3-Years
23%
|
CAGR 5-Years
2%
|
CAGR 10-Years
9%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Accrued Liabilities
$5.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
|
|
Danaher Corp
NYSE:DHR
|
Accrued Liabilities
$3.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
|
Waters Corp
NYSE:WAT
|
Accrued Liabilities
$143m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Accrued Liabilities
$646m
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fluidigm Corp
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
See Also
What is Fluidigm Corp's Accrued Liabilities?
Accrued Liabilities
35.3m
USD
Based on the financial report for Dec 31, 2025, Fluidigm Corp's Accrued Liabilities amounts to 35.3m USD.
What is Fluidigm Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
9%
Over the last year, the Accrued Liabilities growth was -5%. The average annual Accrued Liabilities growth rates for Fluidigm Corp have been 23% over the past three years , 2% over the past five years , and 9% over the past ten years .
